Related Experiment Video

Updated: Jun 1, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Survival and sudden cardiac death after septal ablation for hypertrophic obstructive cardiomyopathy

Morten Kvistholm Jensen1, Ole Havndrup, Christian Hassager

  • 1The Heart Center, Rigshospitalet, Copenhagen University Hospital, Denmark. mortenjensen@dadlnet.dk

Scandinavian Cardiovascular Journal : SCJ
|May 25, 2011
PubMed

Insights

Percutaneous transluminal septal myocardial ablation (PTSMA) for hypertrophic obstructive cardiomyopathy (HOCM) shows similar survival and no increased sudden cardiac death (SCD) risk compared to controls. Long-term outcomes are favorable.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Cardiac Surgery

Background:

  • Hypertrophic obstructive cardiomyopathy (HOCM) presents risks of sudden cardiac death (SCD).
  • Percutaneous transluminal septal myocardial ablation (PTSMA) is a treatment option for HOCM.
  • Long-term survival and SCD risk data post-PTSMA are limited.

Purpose of the Study:

  • To evaluate long-term survival after PTSMA in HOCM patients.
  • To assess the risk of SCD in PTSMA-treated patients.
  • To compare SCD risk factors in PTSMA patients versus hypertrophic cardiomyopathy (HCM) controls.

Main Methods:

  • Survival and SCD were analyzed in 77 PTSMA-treated patients (3.5 ± 2.8 years follow-up).
  • SCD risk stratification was performed in 57 PTSMA patients at long-term follow-up (3.8 ± 2.8 years).
  • PTSMA cohort outcomes were compared to an HCM control cohort and the general population.

Main Results:

  • Five-year survival was 83% in the PTSMA cohort, comparable to HCM controls (79%) and lower than the background population (91%).
  • Five-year survival free of SCD was 94% post-PTSMA, similar to HCM controls (99%).
  • Eight percent of PTSMA patients had ≥2 SCD risk factors at follow-up; no increased SCD risk was observed.

Conclusions:

  • PTSMA-treated patients exhibit survival rates similar to HCM controls.
  • PTSMA does not appear to increase the incidence or future risk of SCD.
  • Excess mortality in PTSMA patients is likely attributable to HCM, not the procedure itself.
Abstract

More Related Videos

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter08:00

Reduction of Iatrogenic Atrial Septal Defects with an Anterior and Inferior Transseptal Puncture Site when Operating the Cryoballoon Ablation Catheter

Published on: June 15, 2015

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...